耐火期
神经科学
多发性骨髓瘤
蛋白酶体
耐火材料(行星科学)
免疫系统
可塑性
生物
骨髓
灵活性(工程)
获得性免疫系统
免疫疗法
医学
表型
转化研究
癌症的体细胞进化
炎症
蛋白酶体抑制剂
神经可塑性
癌症研究
生物信息学
叙述性评论
治疗方法
单克隆抗体
临床试验
抗药性
硼替佐米
基因组
计算生物学
机制(生物学)
作者
Maria Elisa Nasso,Adele Bottaro,Demetrio Gabriele Gerace,Sabina Russo,Donato Mannina,Alessandro Allegra
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2026-06-08
卷期号:18 (12): 1873-1873
被引量:1
标识
DOI:10.3390/cancers18121873
摘要
Relapsed and refractory multiple myeloma remains the principal cause of myeloma-related mortality despite major advances in therapeutic options, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and T-cell-based immunotherapies. Conventional resistance models based on linear genetic clonal evolution inadequately explain reversible drug resistance, heterogeneous responses, and relapse after deep remissions. Emerging data from longitudinal genomics, single-cell analyses, and functional studies support a paradigm in which relapsed and refractory multiple myeloma is driven by adaptive plasticity rather than irreversible genetic change alone. Myeloma cells undergo reversible cell state transitions through transcriptional, epigenetic, metabolic, and proteostatic reprogramming, shaped by bone marrow microenvironmental cues and immune pressure. This narrative review integrates current evidence supporting adaptive plasticity as a central driver of therapeutic failure in relapsed and refractory multiple myeloma and discusses clinical and translational implications, highlighting adaptive treatment strategies and approaches targeting phenotypic flexibility to improve durability of response.
科研通智能强力驱动
Strongly Powered by AbleSci AI